Precision Medicine Guided Treatment for Cancer Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2019-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pain is one of the most burdensome symptoms associated with cancer and its treatment, and opioids are the cornerstone of clinical pain management in cancer patients. Yet, individual patient responses to opioids vary widely, and the patient's genotype contributes to this variability. Specifically, cytochrome P450 2D6 (CYP2D6) genotype has important relevance for response to opioid analgesics that depend on CYP2D6 for bioactivation. Poor metabolizers (PMs) have lower concentrations of active metabolites of codeine (morphine), tramadol (O-desmethyltramadol), oxycodone (oxymorphone), and hydrocodone (hydromorphone), compared to extensive metabolizers (EMs). Morphine and O-desmethyltramadol have 200-fold greater affinity for the µ-opioid receptor than the parent compound, whereas oxymorphone and hydromorphone have 40-fold and 10-fold higher receptor affinity compared to their parent compounds, respectively. Consequently, PMs may fail to derive pain relief from these opioids compared to EMs. Interestingly, the occurrence of side effects may not differ between PMs and EMs so that while PMs may get little to no pain relief from certain opioid analgesics, they may still experience troublesome adverse effects. Intermediate metabolizers (IMs) are also expected to have reduced analgesic response based on their significant reduction in enzyme activity. Conversely, individuals with the UM phenotype may have toxic concentrations of active opioid metabolites, with reports of life-threatening toxicity and death. The µ-opioid receptor gene (OPRM1) is the primary binding site for endogenous opioid peptides and opioid analgesics, and may have additional contributions to opioid response. The investigators propose to examine the effect of CYP2D6 genotype-guided pain management on cancer pain control in study participants and the additional effect of the OPRM1 genotype on response to opioids.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Informing Pain Treatment Using Pharmacogenomic Analysis

NCT06511401

Adult Patients Who Are Receiving Oncologic Care

RECRUITING NA

Individualized Pharmaceutical-care for Inpatients With Cancer Pain

NCT03455023

Cancer Pain

UNKNOWN NA

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

NCT00666211

Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia +8 more

COMPLETED PHASE3

Opiophobia in Adults With Advanced Cancer

NCT07093567

Cancer

ACTIVE_NOT_RECRUITING

Opioid Misuse in Patients with Cancer

NCT06489769

Cancer Opioid Use Opioid Misuse +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a randomized, open label, multi-site clinical trial conducted in UF Health Cancer Center in Gainesville, FL and in Moffitt Cancer Center in Tampa, FL. Each site will be responsible for overseeing patient care and research at their respective facility. This research will examine pain-related outcomes with CYP2D6-guided cancer pain management for study participants. In addition, the investigators will evaluate a prospective cohort study in the same population examining the effect of OPRM1 genetic variants on pain relief and adverse drug effects over time.

Participants will be randomized in a 1:1 manner to receive CYP2D6 genotype-guided (n=50) or non-genotype-guided (traditional, n=50) selection of pain medication. Patients in the genotype arm will be genotyped at baseline for CYP2D6 variants. Participants will fill out the the Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI) questionnaires at baseline. Then, during the clinical visits the same questionnaires will be done during weeks 2, 4, 6, and 8 or by telephone or electronic survey.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain CYP2D6 Polymorphism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genotype Arm

Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).

Group Type EXPERIMENTAL

CYP2D6

Intervention Type GENETIC

Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.

Brief Pain Inventory-Short Form (BPI-SF)

Intervention Type BEHAVIORAL

This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

M.D. Anderson Symptom Inventory (MDASI)

Intervention Type BEHAVIORAL

This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

OPRM1

Intervention Type GENETIC

Genetic testing of the OPRM1 will be performed after week 8.

Traditional Arm

Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).

Group Type ACTIVE_COMPARATOR

CYP2D6

Intervention Type GENETIC

Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.

Brief Pain Inventory-Short Form (BPI-SF)

Intervention Type BEHAVIORAL

This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

M.D. Anderson Symptom Inventory (MDASI)

Intervention Type BEHAVIORAL

This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

OPRM1

Intervention Type GENETIC

Genetic testing of the OPRM1 will be performed after week 8.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CYP2D6

Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.

Intervention Type GENETIC

Brief Pain Inventory-Short Form (BPI-SF)

This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

Intervention Type BEHAVIORAL

M.D. Anderson Symptom Inventory (MDASI)

This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.

Intervention Type BEHAVIORAL

OPRM1

Genetic testing of the OPRM1 will be performed after week 8.

Intervention Type GENETIC

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cytochrome P450 2D6 µ-opioid receptor gene

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of histologically or cytologically proven solid tumor with or without metastasis
* Receiving treatment at UF Health Cancer Center for outpatient pain management with an opioid

Exclusion Criteria

* Undergone surgery within the last three months or are scheduled to undergo surgery during the study period (4 weeks)
* Documented psychiatric or neurological condition that would interfere with study participation
* Liver transplant
* Allergic to opioids

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No